Abstract. Peroxisome proliferator-activated receptor Á (PPARÁ) is a member of the nuclear hormone receptor family. In colon, this transcription factor is involved in differentiation of absorptive cells. PPARÁ participates also in colon carcinogenesis and cancer progression. Two isoforms, namely PPARÁ1 and PPARÁ2, have been described. Recently, new PPARÁ1 transcripts whose translation raises PPARÁ1 protein have been characterised. They differ from each other by combination of untranslated exons localised in the 5' UTR of the PPARG gene. Here, we studied whether such a diversity of PPARÁ transcripts occurs in human colon cell models. Based on bioinformatic analysis, putative untranslated exons were identified in the human PPARG gene. By RT-PCR analysis, we have demonstrated that several of these untranslated exons are included in PPARÁ transcripts from colon-derived cell lines or in those derived from other tissue. Using HT-29 cells, changes in PPARÁ1 mRNA levels were observed after treatment with PPARÁ agonists such as pioglitazone and troglitazone. These modifications correlated with particular PPARÁ transcripts excluding the untranslated exon A2. HT-29 cells treatment with actinomycin D or cycloheximide showed that the presence of PPARÁ mRNA including exon A2 was dependent on de novo protein synthesis. We concluded that diverse PPARÁ1 mRNA exist in colorectal cells. Levels of PPARÁ1 transcript varied according to the phenotype of colon cell model used. We suggest that regulation of PPARÁ1 mRNA levels could be dependent in part on the composition of untranslated exon(s) in the 5' UTR of PPARÁ1 mRNA.
Introduction
Peroxisome proliferator activated receptors (PPAR) belong to the nuclear hormone receptor superfamily (1) . There are three isotypes named PPAR·, PPARß/‰ and PPARÁ (2) . These nuclear receptors act as heterodimers with the 9-cis retinoic acid receptor and bind to a specific DNA sequence, the peroxisome proliferator response element, a direct repeat of the 5'-AGGTCA-3' sequence spaced by one base (3, 4) . After ligand activation, the heterodimer complex regulates the transcription of specific genes involved in several physiological functions (2) . In colon, PPARÁ is implicated in differentiation of absorptive cells (5) , in carcinogenesis or tumour progression even though contradictory results have been obtained in murine and human models (6) .
The PPARÁ gene is localised to chromosome 3, band 3p25 (7) . The open reading frame consists of exons E1-E6 which encode the different domains of the protein. In human, two PPARÁ isoforms have been identified and referred to as PPARÁ1 and PPARÁ2 (7, 8) . PPARÁ2 differs from PPARÁ1 by an additional 28 amino acid NH2-terminal sequence (8) . The 5' UTR region of PPARÁ transcripts, raising PPARÁ1 and -2 proteins, is highly variable and three exons termed A1, A2 and B have been described (9, 10) . Due to different promoter usage and alternative splicing, two other PPARÁ transcripts have been identified and they have been referred to as PPARÁ3 and -Á4 (10, 11) . PPARÁ1 mRNA consists of A1-A2-E1-6 exons, whereas PPARÁ3 mRNA is composed only of A2-E1-6 exons. Both the exons A1 and A2 are not translated. The PPARÁ4 mRNA has a transcription initiation site at the boundary of exon E1 (at position -29 upstream of the start point of exon E1) (11) . All these PPARÁ transcripts generate the same protein PPARÁ1. Other untranslated exons have also been identified in the 5' UTR of PPARÁ mRNA in mouse (12) , in monkey (13) and recently in normal human mammary epithelial and breast cancer cells (14) . Wang et al demonstrated the presence of multiple transcription start sites leading to different PPARÁ1 transcripts observed in mammary epithelial cells and breast cancers cells (14) . The different promoters are thought to mediate specific PPARÁ1 transcript expression in normal and tumoral tissues. In monkey macrophage and human macrophage-derived cell lines, Zhou et al (13) and Chen et al (15) respectively showed the presence of the so-called untranslated exon C and exon D in addition to the previously identified exons A1, A2 and B. Promoter usage and alternative splicing have raised seven PPARÁ transcripts referred to as PPARÁ1-7.
Due to the complexity of the PPARÁ gene, we postulated that in colon cell models the regulation of PPARG gene expression could be the result of multiple promoter usage which in turn generates other transcripts encoding the protein PPARÁ1 than the already described PPARÁ1, 3 or 4 mRNA. Many studies over the last 20 years have reported cancer-specific alternative splicing in the absence of genomic mutations (16) . As well as being associated with cancer, the nature of the alternative gene products is usually consistent with an active role in cancer. Therefore, the alternative splicing process itself is a potential target for gene therapy. Using RT-PCR semi-quantification carried out with polyA + RNA from human colon cells and 5' extension primer experiments, we have demonstrated the presence of different PPARÁ1 transcripts. Treatment of HT-29 cell line, a colon tumour cell model, with PPARÁ agonists, actinomycin D or cycloheximide suggested that the variation in PPARÁ mRNA levels could depend on the nature of PPARÁ mRNA in colon cell model.
Materials and methods
Reagents. Dulbecco's modified Eagle's minimum medium (DMEM), trypsin/EDTA solution, fetal calf serum (FCS), non-essential amino acids solution, and Dulbecco's sodium phosphate buffer (DPBS) were purchased from Eurobio (Les Ulis, France). Taq polymerase, RNAsin, reverse transcriptase (M-MLV) and primers were obtained from Invitrogen Corporation (Paisley, Scotland). Restriction enzymes and protease inhibitor ready-made solution were from Sigma Corporation (St. Louis, MO, USA). BM Chemiluminescence revelation kit was from Roche (Mannheim, Germany). Commercial polyclonal rabbit antibodies against PPARÁ were from Cayman (Tallin, Estonia). Polyclonal rabbit antibodies against ß-actin were purchased from Sigma. Polyclonal rabbit antibodies against catalase were prepared and characterized as described before (17) . Troglitazone was purchased from Cayman; pioglitazone was a gift from Tadeka Chemicals Industries Ltd. (Osaka, Japan). Other reagents were of analytical grade. A549 cells were obtained from N. Frossard (EA 3771, Strasbourg, France). HepG2, THLE, MCF-7, HeLa cells are part of the laboratory cell-line collection. Cells, except Caco-2 cells, were cultured in DMEM-25 mM glucose containing 10% (v/v) heat-inactivated (30 min at 56˚C) FCS and 2 mM L-glutamine, and they were seeded at a concentration of 10 5 cells/ml. Caco-2 cells were cultured in the same medium containing 20% (v/v) heat-inactivated FCS and 1% (v/v) non-essential amino acids. Seeding was 6x10 4 cells/ml. All cells were grown in a 5% CO 2 humidified atmosphere. Medium was changed daily, 48 h after seeding. After 5 and 15 days of culture, cell layers were washed twice with cold-DPBS for 5 min. Cell layers were frozen at -80˚C until RNA extraction or cell homogenate preparation.
Cell treatments. Agonist treatment was carried out 48 h after HT-29 cell seeding for five days. Medium containing 1 or 10 μM troglitazone or pioglitazone and 1 μM 9-cis retinoic acid was changed daily. Cell layers were then washed three times with cold DPBS and stored at -80˚C. HT-29 cells were assessed after two and five days for each treatment by using Trypan blue staining at least four times. Results are expressed at mean ± SD. Five and 15-day-old HT-29 cells were treated in the presence of 1 or 10 μg/ml cycloheximide or 1 and 10 μM actinomycin D for 24 h. Thereafter, cell layers were washed twice with cold-DPBS, and stored at -80˚C until total RNA extraction.
RT-PCR analysis and semi-quantification of PPARÁ transcripts. Total RNA was phenol/chloroform extracted (18) . PolyA + RNAs were purified on oligo dT cellulose according to standard protocol (19) . cDNAs were obtained by reverse transcription reaction according to standard protocol with M-MLV reverse transcriptase (200 U) and 1 μg of total or polyA + RNA. cDNA amplification was carried out in 20 mM Tris-HCl (pH 8.4) buffer containing 50 mM KCl, 1.5 mM MgCl 2 , 5 U of RNAsin, 0.2 mM dXTP, 0.4 μM each selected sense and antisense primers, 2 μl of reverse transcription sample and 2.5 U of Taq polymerase for 35 cycles (95˚C, 30 sec; annealing temperature at Tm of the primers, 30 sec; 72˚C, 30 sec) followed by an extension step at 72˚C for 5 min. Primers used in this study are listed in Table I . GAPDH was used as an internal control. Amplicons were analysed on a 2% (p/v) TBE-agarose gel. The bands obtained were quantified (Gel Doc, Bio-Rad, Hercules, USA). Results are expressed as the ratio (PPARÁ isoform human /GAPDH human ) in arbitrary units. HinfI restriction enzyme which specific site is present only in exon A2 was used to verify the presence of exon A2 in amplicons obtained with primer sense A0, A1 or A5 and antisense primer E1. All PCR-products described here were cloned in pBlueScript plasmid and sequenced (INRA, Champenoux, France). We did not find any difference in sequence with those described on the UCSC Genome site. Total RNA from SW480, HCT EB and LS174T cells were prepared by T.L. as decribed above. Table I . 5' end primer labeling was carried out with 32 P[Á]-ATP using a labelling kit purchased from AmershamBiosciences (Orsay, France). Lengths of extension products were estimated in 5% acrylamide/7 M urea gel prepared in TBE buffer.
Western blotting. Cell homogenates were prepared in freshly made extraction buffer according to Mansen et al (21) . Protein (50 μg) was resolved in 10% SDS-PAGE (22) . Proteins were transferred onto PVDF membranes (23) and they were further proceeded for chemiluminescence detection according to the manufacturer's protocol. Dilution of the first antibody solution was 1:1,000 for polyclonal rabbit antibodies directed against PPARÁ, 1:20,000 for polyclonal rabbit antibodies against ß-actin, and 1:1,000 for polyclonal rabbit antibodies against catalase.
Statistics. All the statistics were computed using SPSS v11.5 software (SPSS Inc., Chicago, IL, USA). For the comparison of the variation of PPARÁ transcript contents along cell culture duration, one way ANOVA was performed with Bonferroni post-hoc test for the multiple comparisons. Differences were considered significant at P<0.05.
Results

Untranslated exons mapping on the PPARG gene.
We first compiled the representative sequences of all spliced EST present in the data bank resources (Table II) . In order to map putative and known untranslated exons of the PPARG gene, we looked for: a) cryptic splice sites as 5'-aggu-3' and 5'-agg-3'; b) intronic polypyrimidine sequences between a putative acceptor splice site and an A-branch site were localised in order to define the boundaries of internal exon; c) the presence of a putative Inr element was investigated in the genomic region upstream of each known or putative first exon. In addition to the known exons namely A, A0, A1, A2 and B, we found two additional exons A4 and A5 (Fig. 1b) . No amplification product was obtained when RT-PCR was carried out with primers designed in exon A or A4 and E1, neither in colon normal-matched and tumour sample, nor in colon adenocarcinoma-derived cell lines (data not shown). Zhou et al (13) have suggested that exon C and D identified in monkey macrophages may exist in the human PPARG gene. Sequence alignments demonstrated that <50% similarity exists between the sequence of exon D from monkey Table I . Sequences of primers used in this study. 
The E1a antisense primer is localised at the 5' end of exon E1. It was used to amplify the untranslated PPARÁ1 exonic regions composed with combined exons A1-A2, A5-A2 and A2 or A1 alone.
b The E1b antisense primer is localised at the 3' end of exon E1. It was used to amplify the untranslated PPARÁ1 exonic regions composed with combined exons A0-A2 or A0 alone.
and that of the corresponding human genomic sequence. We decided therefore to exclude exon D from the present study. Likewise, the sequence of exon C is present in the human PPARG gene. However, using RT-PCR experiments, we did not observe the presence of any transcript including exon C joined to E1 neither in human colorectal-derived cells ( Fig. 2 ) nor in human colorectal samples (data not shown). In contrast, we amplified the exonic region between exons C and E1 when RT-PCR was performed with total RNA extracted from Vero cells in a control experiment (Fig. 2) . Table II . Selected human EST used to map the untranslated exons on the PPARG gene. 
Presence of PPARÁ protein in colon derived
Numbers represent the sequence length in nucleotides of untranslated exon.
- RT-PCR experiments were performed with specific primers designed from exon C and exon E1 of the PPARG gene.
absorptive (24) and mucus-secreting cells (25) , respectively. HT-29 and HCT116 cells remained undifferentiated in the same culture delay. As previously shown (26) , catalase content used as a marker of differentiation was increased during spontaneous differentiation process occurring in Caco-2 cells, but also in HT-29 MTX 10 -5 M Rev cells. We demonstrated that PPARÁ protein was present in these cells with an estimated Mr at 50 kDa (Fig. 3) . In Caco-2 or HT-29 MTX 10 -5 M Rev homogenates, PPARÁ protein content was increased from 5-15 days in culture whereas it decreased in HT-29 during the same culture duration. In HCT116 cells, PPARÁ protein corresponded to a band estimated at 47 kDa. The reason for such a difference is not clear. We suggest that PPARÁ protein is degraded in this cell line and that the observed band is the result of receptor degradation as previously reported (7, 27) . (Table I) or exon E4 and E6 (a). The amplified regions are named according to the composition of untranslated exon fused to exon E1. The intensities of the bands were quantified and the ratio between intensities of PPARÁ1 exonic regions and GAPDH were determined at 5 (white bar) and 15 days (grey bar) (b). The bar graphs represent the mean ± SD from 3 independent experiments. Significant difference (*) at P-value <0.05 (ANOVA) are shown in (b).
Presence of different PPARÁ1 transcripts in colon derived
Rev differentiating cells, whereas they decreased in HT-29 and HCT116 cells. We investigated which transcripts may account for the total level of PPARÁ1 mRNA. Several exonic regions were amplified with sense primer designed for each untranslated exon and antisense primer designed for exon E1. Since PPARÁ was present in the four cell lines tested, semi-quantification of PPARÁ1 transcripts were planed using polyA + RNA prepared from cells cultured for 5 and 15 days (Fig. 4b) .
Using exon A0 or A1 sense primer and exon E1 antisense primer (Fig. 4a) , two PCR products were obtained with an estimated length of 313 and 241 bp or 176 and 102 bp, respectively. The longest PCR products included exon A2 as demonstrated by digestion of the PCR product with HinfI Total RNA was extracted from cell layers and submitted to RT-PCR analysis using primers designed in untranslated exon Ai and E1 or in exon E4 and E6. The intensities of the bands were quantified and the ratio between intensities of each PPARÁ1 exonic region and GAPDH was calculated. The bar graphs represent the mean ± SD from 3 independent experiments. Significant differences (*) at P-value <0.05 are shown (ANOVA). P9C, T9C: combined treatment respectively with pioglitazone or troglitazone and 9-cis retinoic acid (see Materials and methods).
which restriction site is present only in exon A2 (data not shown). Likewise, amplification with sense primer in exon A5 and antisense primer in exon E1 gave a single band estimated at 150 pb which contained exon A2 (Fig. 4a) . Amplification was also carried out with sense primer designed in exon A2 (Fig. 4a) . The obtained PCR products estimated at 108 bp account for all the mRNA including exon A2 or for the mRNA containing exclusively exon A2 in its 5' UTR, namely PPARÁ3 mRNA (10) .
Semi-quantification of each exonic region suggested that the transcripts for the so-called PPARÁ1 isoform were mainly represented by combination of exons A1-A2-E1-6 as observed previously (9) . The other mRNAs containing the untranslated region A0-A2, A5-A2, A0 alone or A1 alone, were less abundant in all colon cell lines tested. However, the relative levels of each mRNA depended on cell line and culture duration. The transcripts containing the A5-A2 region decreased in Caco-2 and HT-29 cells whereas they increased in HCT116 cells (Fig. 4b) . Transcripts containing the A0-A2 region decreased in HT-29 MTX 10 -5 M Rev cells. Furthermore, each PPARÁ1 transcript studied here was recovered in the other cell lines tested but with strong differences in the mRNA levels (Fig. 5) . For example, transcripts containing A5 were detected in MRC5 and HeLa cells, but we failed to detect them in HepG2 and THLE cells. PPARÁ1 transcripts containing the A1-A2 exonic region (band estimated at 176 bp) were more abundant in MRC5, HeLa or MCF-7 than in A-549 cells. At least in HepG2, PPARÁ1 level was represented mainly by transcripts that contained untranslated exonic region A0-A2 or A0 alone. In other colorectal cell lines used, higher expression of exonic region A5-A2-E1 was observed in SW480, SW620, HCT EB and LS174T cells (Fig. 5) .
Effect of agonist treatment on PPARÁ1 mRNA level in HT-29 cells.
HT-29 cells were treated with troglitazone or pioglitazone in the presence of 9-cis retinoic acid during the proliferation stage of the cells, in order to investigate possible changes in PPARÁ1 transcripts levels (Fig. 6b) . Since PPARÁ agonists have been shown to block cell growth and to increase cell anoikis, we first counted cell populations during dose-(1 or 10 μM agonist and 1 μM 9-cis retinoic acid) and time course-treatment (5 days). There were no significant variations in cell counts at whatever the treatment used (Fig. 6a) . A significant increase was observed only in PPARÁ mRNA content including untranslated exon A1 (3 times), A0 (2 times) or exonic region A5-A2 (5 times). No significant alteration was observed in the mRNA levels of the other transcripts, which included untranslated exon A2 in exonic region A1-A2 and A0-A2 (Fig. 6b) .
Effect of actinomycin D and cycloheximide on PPARÁ1 mRNA level in HT-29 cells.
Since increased PPARÁ mRNA levels were observed for transcripts excluding A2 exon (except for the A5-A2 untranslated region), we hypothesised that the presence of A2 untranslated exon may contribute to PPARÁ mRNA stability. Therefore, HT-29 cells were cultured for 5 or 15 days, then treated with actinomycin D (1 or 10 μM) or cycloheximide (1 or 10 μg/ml) for 24 h (Fig. 7a and b,  respectively) . RT-PCR analysis was limited to amplification of E4-E6 and A2-E1 exonic regions. Cells treated with actinomycin D at 5 days of culture exhibited a 70% decrease ) for 24 h. Total RNA was extracted and submitted to RT-PCR using primers designed in exon E4-E6 and exon A2 and E1, respectively. The intensities of the bands were quantified and the ratios between intensities of each PPARÁ1 exonic region and GAPDH were calculated. The bar graphs represent the mean ± SD from 3 independent experiments. Significant difference (*) at P-value <0.05 are shown (ANOVA).
in PPARÁ1 initial level estimated with primers designed in exon E4 and E6 (Fig. 7a) . Amplification product of the exonic region containing exon A2 was reduced to 50%. HT-29 cells were less drug-sensitive after 15 days in culture, since mRNA levels were only reduced with high drug concentration (a 40% decrease). We next treated cells with cycloheximide for 24 h in order to verify if PPARÁ mRNA levels could be altered by inhibition of protein synthesis (Fig. 7b) . In 5-day-treated HT-29 cells, no change was found when PPARÁ levels were quantified with primers designed in exon E4 and E6. An 85%-decrease was observed in PPARÁ1 mRNA level estimated with primers designed in exon A2 and E1. In contrast, alteration in PPARÁ mRNA levels in 15-dayold HT-29 cells was only obtained with high concentrations of cycloheximide (a 60% decrease). Our results suggested that during the proliferation stage of HT-29 cells, two mechanisms regulate changes in PPARÁ transcript levels; firstly, whatever the mechanism, one part of PPARÁ transcript seems to be dependent on the presence of de novo protein synthesis.
Secondly, part of the PPARÁ transcripts turnover is high as demonstrated by actinomycin D treatment and quantification with primers designed in exon E4 and E6.
5'-Primer extension.
We performed 5' primer extension with polyA + prepared from 15-day-old adenocarcinoma cells (Fig. 8) . As shown in Fig. 8a , we failed to detect extension product corresponding to exon A2 alone (estimated length at 52 bp). These results contrasted with previous work demonstrating that exon A2 alone constitutes a specific transcript id est PPARÁ3 in human cell models (10) . Experiments were also extended with antisense primer designed in exon A1, A5 and E1. Surprisingly, several unexpected extension products were obtained starting with A1, A2, A5 and E1 primers. Our results suggested that either unknown exon may exist and participate in the diversity of PPARÁ1 transcripts or the lengths of known exons are greater than previously described.
Discussion
PPARÁ has been implicated in colorectal cancer and is thought to exhibit a protective action when the receptor is activated with a specific agonist (28) . This protective role has been studied in colorectal cancer-derived cells and results suggest that PPARÁ agonist treatments lead to inhibition of cell growth, enhancement of protein markers for differentiation and/or induction of cell apoptotic processes. The agonist effect depends largely on the cell line tested and is dose-dependent (29) .
In colon and colorectal cell lines, PPARÁ1 is the main protein isoform (30, 31) . Recently, several transcripts resulting from alternative promoter usage and splicing of untranslated exons of the PPARG gene have been identified (14) . Bioinformatic analysis based on previous data (9, 10, 13, 14) and representative EST alignment (Table II) lead us to complete a previous map of known and putative untranslated exons named exon A, A0-A5 (Fig. 1) . However, using RT-PCR experiments, we failed to detect A, A3 and A4 and therefore it is likely that these exons are not included in human colon PPARÁ1 mRNA. Wang et al demonstrated that exons A and A3 are used in normal and tumoral mammary tissues (14) . Exon A3 expression is restricted to normal mammary tissue suggesting a tissue specific expression. In the present study, similar results have been obtained with exon A5, whose expression is higher in fibroblast or HeLa cells than in colorectal cancer-derived cells (Figs. 5 and 4, respectively) . Our results demonstrated that mRNA composed of the exonic region A5-A2 is higher in proliferating cells in three out of four cell-lines tested (Fig. 4b) .
In colorectal cancer-derived cells, we showed that several transcripts encoding PPARÁ1 protein are present as demonstrated by RT-PCR and by 5' primer extension experiments (Figs. 4, 5 and 8) . Our results support evidence that PPARÁ1 transcription depends on multiple promoter usage and alternative splicing leading to fine transcription regulation within the cells as described within macrophages and breast cancer cells (13) (14) (15) . Likewise, in pre-adipocytes and in mature adipocytes, PPARÁ1 mRNA levels remain constant whereas PPARÁ2 mRNA levels increase upon adipocyte differentiation (32) (33) (34) . When colon cancer-derived cells were treated with PPARÁ agonists (Fig. 6b) , the PPARÁ mRNA level was modified only for the combined A0-, A1-, and A5-A2-PPARÁ1 transcripts, the levels of the other transcripts remained constant. It must be noted that we used PPARÁ agonist concentrations that did not induce cell apoptosis as it has been demonstrated by others (29, 35, 36) . Additional treatments either with actinomycin D (Fig. 7a) or with cycloheximide (Fig. 7b) suggest that PPARÁ transcript content depends on RNA flux controlled in two ways, high mRNA turnover and protein synthesis-dependent stability of mRNA. Moreover, we show here that increases in the PPARÁ1 mRNA levels in response to receptor agonist treatment were associated with increases in particular transcripts levels (Fig. 6b) . Similar results were obtained recently with human THP-1 macrophages (15) . Treatment with agonist increased PPARÁ transcript isoform composed of particular exon C and D (and named PPARÁ5 isoform), whereas agonist treatment leads to decrease PPARÁ1 and Á2 mRNA levels. We suggested that A2 could participate to structural stability of PPARÁ mRNA. Taken together, our results did not confirm previous work demonstrating that PPARÁ3 is the main isoform in colon cells models (26, 37) . Using 5' extension experiment, we failed to demonstrate any extension product at the expected length (at 52 bp) when experiments were carried out with antisense primer designed in exon A2 (Fig. 8) . Likewise, when HT-29 cells were treated with PPARÁ agonist at low concentration, no change was observed in the mRNA isoform levels corresponding to the so-called PPARÁ1 or PPARÁ3 transcripts, as demonstrated by others using oxidized metabolites of linoleic acids as endogenous ligands for PPARÁ (37) . Others studies are needed to clarify the impact of specific treatment to the expression of each particular PPARÁ1 transcript isoform. The role of each PPARÁ1 transcript has to be established in colon cell model, even though the implication of the receptor in intestinal cell regulation begins to emerge (5) .
Alternative splicing is a crucial mechanism to explain the diversity of gene expression. This mechanism has been shown to be altered in cancer (16) . The involvement of PPARÁ mRNA diversity had to be stated during development, proliferation or differentiation in the case of colon cells. As demonstrated recently, alternative splicing could explain the diverse modifications observed in signalling pathway from embryonic stem cells to tissue stem cells (38) . In the present work, we suggested that alternative splicing could modify the diversity and the levels of PPARÁ transcripts. This process could change the transcription rate in response to a specific signalling pathway or by ligand coactivatordependent recruitment, as suggested by Chen et al (15) . Finally, using 5' primer extension (Fig. 8) we detected unexpected 5' mRNA regions, which could not be assigned to association of some known exon A1. It is possible that other exonic combinations may exist as demonstrated recently in human THP-1 macrophages (15) . It will be of interest to investigate if other untranslated exons may exist or not. In conclusion, we reported that in colon cancerderived cells, diverse transcripts encoding PPARÁ1 protein exist due to specific promoter usage and alternative splicing. The respective levels of the transcripts depend on the colon cell model used.
